H. Platt

发表

Effi cacy and safety of grazoprevir ( MK-5172 ) and elbasvir ( MK-8742 ) in patients with hepatitis C virus and HIV co-infection ( C-EDGE CO-INFECTION ) : a non-randomised , open-label trial

C. Katlama, M. Saag, J. Rockstroh, 2015 .

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

C. Katlama, M. Saag, J. Rockstroh, 2015, The lancet. HIV.

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

D. Greenberg, C. Acosta, B. Tapiéro, 2020, The Pediatric infectious disease journal.

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study

G. Everson, E. Verna, I. Jacobson, 2019, Clinical and translational gastroenterology.

Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.

E. Asante-Appiah, R. Flisiak, B. Nguyen, 2016, Journal of hepatology.

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.

N. Gallagher, R. Mularski, Julie M. Skinner, 2022, The Lancet. Infectious diseases.

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection

R. Talwani, S. Zeuzem, J. George, 2018, Journal of Gastroenterology.

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

B. Conway, F. Altice, G. Dore, 2017 .

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

D. Nickle, B. Conway, F. Altice, 2016, Annals of internal medicine.

Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

E. Asante-Appiah, B. Conway, F. Altice, 2022, Annals of Internal Medicine.

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).

R. Dagan, M. Haranaka, A. Pedley, 2021, Vaccine.

A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II)

Julie L Gardner, P. Silas, E. Zissman, 2020, Human vaccines & immunotherapeutics.

Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study.

M. Zoli, E. Giannini, F. Farinati, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The albumin‐bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV‐associated hepatocellular carcinoma

D. Pinato, M. Nelson, B. Mínguez, 2018, Alimentary pharmacology & therapeutics.

C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

B. Conway, F. Altice, G. Dore, 2016 .

P09 A Phase 2, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (V116) in adults ≥50 years

R. Mularski, Neil J. Fraser, A. Sapre, 2023, JAC-Antimicrobial Resistance.

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults

S. Kharit, Natalie Banniettis, H. Platt, 2021, Human vaccines & immunotherapeutics.

Advance Publication by J-STAGE Japanese Journal of Infectious Diseases Immunogenicity and Safety of KM-248, a Combined Measles, Mumps, and Rubella vaccine, and the Noninferiority to a Measles Vaccine in Healthy Japanese Children; Phase 3 Randomized Multicenter Single-Blind Clinical Trial

K. Ueda, H. Platt, S. Tochihara, 2021 .

Design and Evaluation of a Bacterial Clinical Infectious Diseases Ontology

Chunhua Weng, Mary Regina Boland, Claire L. Gordon, 2013, AMIA.

Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared With 13- valent Pneumococcal Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE).

A. Pedley, L. Musey, M. Sawata, 2022, Japanese journal of infectious diseases.

Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection

B. Conway, F. Altice, E. Gane, 2022, Journal of addictive diseases.